IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's CEO and co-founder, William Ho, will deliver a presentation on Tuesday, February 25, 2025, at 11:00 a.m. ET.
The presentation will be accessible through a live webcast, with a replay option available afterward. Interested parties can access the webcast through the provided link or find it in the 'Events and Presentations' section under News & Presentations on IN8bio's investor relations website.
IN8bio (Nasdaq: INAB), un'azienda biofarmaceutica in fase clinica specializzata in terapie con cellule T gamma-delta, ha annunciato la sua partecipazione alla 3ª Conferenza Virtuale Annuale sulla Terapia Cellulare di H.C. Wainwright. Il CEO e co-fondatore dell'azienda, William Ho, terrà una presentazione martedì 25 febbraio 2025, alle 11:00 ET.
La presentazione sarà accessibile tramite un webcast dal vivo, con un'opzione di replay disponibile successivamente. Le parti interessate possono accedere al webcast tramite il link fornito o trovarlo nella sezione 'Eventi e Presentazioni' sotto Notizie e Presentazioni sul sito web delle relazioni con gli investitori di IN8bio.
IN8bio (Nasdaq: INAB), una empresa biofarmacéutica en etapa clínica especializada en terapias con células T gamma-delta, ha anunciado su participación en la 3ª Conferencia Virtual Anual de Terapia Celular de H.C. Wainwright. El CEO y cofundador de la empresa, William Ho, realizará una presentación el martes 25 de febrero de 2025, a las 11:00 a.m. ET.
La presentación será accesible a través de una transmisión en vivo, con una opción de repetición disponible posteriormente. Las partes interesadas pueden acceder a la transmisión a través del enlace proporcionado o encontrarla en la sección 'Eventos y Presentaciones' bajo Noticias y Presentaciones en el sitio web de relaciones con inversores de IN8bio.
IN8bio (Nasdaq: INAB), 감마-델타 T 세포 치료를 전문으로 하는 임상 단계의 생명공학 회사가 H.C. Wainwright 제3회 연례 세포 치료 가상 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO이자 공동 창립자인 William Ho는 2025년 2월 25일 화요일 오전 11:00 ET에 발표를 진행할 예정입니다.
발표는 라이브 웹캐스트를 통해 접근할 수 있으며, 이후 다시 볼 수 있는 옵션도 제공됩니다. 관심 있는 분들은 제공된 링크를 통해 웹캐스트에 접근하거나 IN8bio의 투자자 관계 웹사이트의 뉴스 및 발표 섹션 아래 '이벤트 및 발표'에서 찾을 수 있습니다.
IN8bio (Nasdaq: INAB), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules T gamma-delta, a annoncé sa participation à la 3ème Conférence Virtuelle Annuelle sur la Thérapie Cellulaire de H.C. Wainwright. Le PDG et co-fondateur de l'entreprise, William Ho, fera une présentation le mardi 25 février 2025, à 11h00 ET.
La présentation sera accessible via un webinaire en direct, avec une option de rediffusion disponible par la suite. Les parties intéressées peuvent accéder au webinaire via le lien fourni ou le trouver dans la section 'Événements et Présentations' sous Actualités et Présentations sur le site web des relations investisseurs d'IN8bio.
IN8bio (Nasdaq: INAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gamma-Delta-T-Zelltherapien spezialisiert hat, hat seine Teilnahme an der 3. jährlichen virtuellen Zelltherapie-Konferenz von H.C. Wainwright bekannt gegeben. Der CEO und Mitbegründer des Unternehmens, William Ho, wird am Dienstag, den 25. Februar 2025, um 11:00 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast zugänglich sein, mit einer anschließenden Wiedergabeoption. Interessierte Parteien können über den bereitgestellten Link auf den Webcast zugreifen oder ihn im Abschnitt 'Veranstaltungen und Präsentationen' unter Nachrichten & Präsentationen auf der Investor-Relations-Website von IN8bio finden.
- None.
- None.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:
H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Date/Time Tuesday, February 25, 2025, at 11:00 a.m. ET.
Webcast Link https://journey.ct.events/view/acb6057e-9d9b-427e-b490-eaf85a5c2910
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Investor & Corporate Contact
Glenn Schulman, PharmD, MPH
IN8bio, Inc.
203.494.7411
gdschulman@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When is IN8bio (INAB) presenting at the H.C. Wainwright Cell Therapy Conference 2025?
How can investors watch IN8bio's presentation at the H.C. Wainwright conference?
What type of therapies does IN8bio (INAB) specialize in?
Will there be a replay available of IN8bio's H.C. Wainwright conference presentation?
